The relationship between NY-ESO-1 expression and degree of CD8 tumor infiltrating lymphocytes in TNBC.

<p>This figure shows the relationship between NY-ESO-1 expression and degree of CD8 tumor infiltrating lymphocytes in TNBC.</p

Induction of NY-ESO-1 by decitabine and 5-azacytidine.

<p>Photomicrograph showing the ability of decitabine and 5-azacytidine to induce of NY-ESO-1 <i>in vitro</i> in MCF-7 cells.</p

Characteristics of NY-ESO-1 positive TNBC patients without NY-ESO-1 antibodies.

<p>Characteristics of NY-ESO-1 positive TNBC patients without NY-ESO-1 antibodies.</p

NY-ESO-1 expression by IHC compared with a negative IgG control.

<p>Photomicrograph of NY-ESO-1 expression by immunohistochemistry side by side compared with a negative IgG control.</p

Patient characteristics.

1<p>These are not accurate reflections of the differences between TNBC and ER+/HER2- due to the sampling method.</p>2<p>LVI is lymphovascular invasion.</p

Extent of CD8 infiltration in triple negative tumors.

<p>This figure demonstrates the extent of CD8 infiltration in triple negative breast specimens.</p

PFS by NY-ESO-1 expression in TNBC.

<p>Kaplan-Meier curve showing PFS differences in patients with TNBC stratified by NY-ESO-1 expression.</p

OS by NY-ESO-1 expression in TNBC.

<p>Kaplan-Meier curve showing OS differences in patients with TNBC stratified by NY-ESO-1 expression.</p

NY-ESO-1 expression frequency by IHC.

<p>NY-ESO-1 expression frequency by IHC.</p

Principal components plots of AABC and selected HapMap samples.

<p>Principal components plots of AABC and selected HapMap samples.</p